Table 1.

Summary of Phase I clinical trials

Authors	Year	Number of patients	Study design	Dose escalation	Dosing frequency	Grade 3 or 4 adverse events	Maximum tolerated dose
Krop et al38	2010	24	Phase I single-arm	0.3–4.8 mg/kg	Every 3 weeks	Thrombocytopenia, pulmonary hypertension	3.6 mg/kg every 3 weeks
Beeram et al39	2012	28	Phase I single-arm with additional patients added later at maximum dose	1.2–2.9 mg/kg	Weekly	Thrombocytopenia	2.4 mg/kg weekly